trial · primary record
AZD6244
Neurofibromatosis 1
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 99 |
| Primary completion | 2032-01-01 |
| Primary endpoint | Ph2: Evaluate the confirmed partial and complete response rate of selumetinib in children and young adults with NF1 and inoperable PN. |
| Registry ID | NCT01362803 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:17.845Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT01362803
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.